In a report published Friday, Credit Suisse analyst Glen Santangelo reiterated an Outperform rating on Cardinal Health CAH, and slightly raised the price target from $51.00 to $52.00.
In the report, Santangelo noted, “We are adjusting our model following the F3Q beat and updated guidance. Our new F13, F14, and F15 estimates are $3.72, $3.56, and $3.87 from $3.51, $3.63, and $3.93, respectively. Our model incorporates the latest assumptions around the WAG loss, CVS repricing, the AssuraMed deal, and capital deployment priorities. Our new PT of $52 (from $51) assumes the shares can trade at roughly 14x our C14 estimate of $3.71. We assign a slightly higher target multiple given the removal of the WAG & CVS overhangs.”
Cardinal Health closed on Thursday at $46.16.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in